Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Clinical trial NCT01868997 · COMPLETED

Trial details

NCT number: NCT01868997
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Thyroid Associated Ophthalmopathies Thyroid-Associated Ophthalmopathy

Start date: 2013-07-01
Primary completion: 2016-03-01
Enrollment: 88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.